Cited by 889Cancer therapeutics and mechanismsBioactive Compounds and Antitumor AgentsMetal complexes synthesis and properties

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

Open access

Tewey, K M, Chen, G L, Nelson, E M, Liu, L F·1984·Journal of Biological Chemistry

DOI 10.1016/s0021-9258(17)47282-6

Open this paper in CoChat — free account

Abstract

Many intercalative antitumor drugs have been shown to induce reversible protein-linked DNA breaks in cultured mammalian cells. Using purified mammalian DNA topoisomerase II, we have demonstrated that the antitumor drugs ellipticine and 2-methyl-9-hydroxyellipticine (2-Me-9-OH-E+) can produce reversible protein-linked DNA breaks in vitro. 2-Me-9-OH-E+ which is more cytotoxic toward L1210 cells and more active against experimental tumors than ellipticine is also more effective in stimulating DNA cleavage in vitro. Similar to the effect of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) on topoisomerase II in vitro, the mechanism of DNA breakage induced by ellipticines is most likely due to the drug stabilization of a cleavable complex formed between topoisomerase II and DNA. Protein denaturant treatment of the cleavable complex results in DNA breakage and covalent linking of one topoisomerase II subunit to each 5'-end of the cleaved DNA. Cleavage sites on pBR322 DNA produced by ellipticine or 2-Me-9-OH-E+ treatment mapped at the same positions. However, many of these cleavage sites are distinctly different from those produced by the antitumor drug m-AMSA which also targets at topoisomerase II. Our results thus suggest that although mammalian DNA topoisomerase II may be a common target of these antitumor drugs, drug-DNA-topoisomerase interactions for different antitumor drugs may be different.

Integrity signals

Registry

Crossref · 10.1016/s0021-9258(17)47282-6

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

DNA Topoisomerases
Gellert, M. F. (1981) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.50.070181.004311 · Cited by 990
DNA Gyrase and the Supercoiling of DNA
Cozzarelli, N. R. (1980) · Science · doi:10.1126/science.6243420 · Cited by 720
DNA Modification and Cancer
Waring, M. J. (1981) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.50.070181.001111 · Cited by 690
The Anticancer Agent Adriamycin Can Be Actively Cytotoxic Without Entering Cells
Triton, T. R., & Yee, G. K. (1982) · Science · doi:10.1126/science.7089561 · Cited by 573
Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.
Nelson, E. M., Tewey, K. M., & Liu, L. F. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.5.1361 · Cited by 561
Self-citation
Cleavage of DNA by mammalian DNA topoisomerase II.
Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., & Chen, G. L. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43815-4 · Cited by 534
Self-citation
Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break.
Liu, L. F., Liu, C.-C., & Alberts, B. (1980) · Cell · doi:10.1016/s0092-8674(80)80046-8 · Cited by 486
Self-citation
Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin
Zwelling, L. A., Michaels, S., Erickson, L. C., Ungerleider, R. S., Nichols, M., & Kohn, K. W. (1981) · Biochemistry · doi:10.1021/bi00526a006 · Cited by 374
A homogeneous type II DNA topoisomerase from HeLa cell nuclei.
Miller, K. G., Liu, L. F., & Englund, P. T. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52552-2 · Cited by 359
Self-citation
Terminal stages of SV40 DNA replication proceed via multiply intertwined catenated dimers
Sundin, O. H., & Varshavsky, A. J. (1980) · Cell · doi:10.1016/0092-8674(80)90118-x · Cited by 354

Show all 39 references

Research works printed but not linked: 3

Zwelling, 1982, Cancer Res., 42, 2687
Burr-Furlong, 1978, Cancer Res., 38, 1329
Pommier, 1982, Biochem. Biophys. Res. Commun., 77, 1150

Sorted by citations

Items 301–400 of 889

Mitoxantrone in the treatment of acute myelogenous leukemia: a review
Thomas, X., & Archimbaud, E. (1997) · Hematology and Cell Therapy · doi:10.1007/s00282-997-0163-8 · Cited by 49
Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines
Pommier, Y. G., Covey, J. M., Kerrigan, D., Mattes, W. B., Markovits, J., & Kohn, K. W. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90329-7 · Cited by 49
Fragmentation of centromeric DNA and prevention of homologous chromosome separation in male mouse meiosis in vivo by the topoisomerase II inhibitor etoposide
Kallio, M. J., & Lähdetie, J. (1996) · Mutagenesis · doi:10.1093/mutage/11.5.435 · Cited by 49
Induction of a heat-stable topoisomerase II-DNA cleavable complex by nonintercalative terpenoides, terpentecin and clerocidin.
KAWADA, S.-Z., Yamashita, Y., Fujii, N., & Nakano, H. (1991) · PubMed · Cited by 49
Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics
Earl, D. C., Ferrell, P. B., Leelatian, N., Froese, J. T., Reisman, B. J., Irish, J. M., & Bachmann, B. O. (2018) · Nature Communications · doi:10.1038/s41467-017-02470-8 · Cited by 48
Synthesis and evaluation of antitumor activity of novel 1,4-Naphthoquinone derivatives (IV)
Kim, B., Yoo, J., Park, S., Jung, J., Cho, H., & Chung, Y. (2006) · Archives of Pharmacal Research · doi:10.1007/bf02974272 · Cited by 48
Isodiospyrin as a novel human DNA topoisomerase I inhibitor
Ting, C., Hsu, C.-T., Hsu, H.-T., Su, J.-S., Chen, T.-Y., Tarn, W., Kuo, Y., Whang‐Peng, J., Liu, L. F., & Hwang, J. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.07.003 · Cited by 48
Self-citation
Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC lung cancer cooperative group
Sahmoud, T., Postmus, P. E., van Pottelsberghe, C., Mattson, K. V., Tammilehto, L., Splinter, T. A. W., Planting, A. S. T., Sutedja, T. G., von Pawel, J., van Zandwijk, N., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00183-4 · Cited by 48
Amiloride intercalates into DNA and inhibits DNA topoisomerase II.
Besterman, J. M., Elwell, L. P., Blanchard, S. G., & Cory, M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45208-8 · Cited by 48
Chronic oral etoposide
Greco, F., Johnson, D. H., & Hainsworth, J. D. (1991) · Cancer · doi:10.1002/1097-0142(19910101)67:1+ · Cited by 48
Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells
Glisson, B. S., Smallwood, S. E., & Ross, W. E. (1984) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(84)90080-0 · Cited by 48
Reduced DNA topoisomerase II activity and drug-stimulated DNA cleavage in 9-hydroxyellipticine resistant cells
Charcosset, J., Saucier, J.-M., & Jacquemin‐Sablon, A. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90573-4 · Cited by 48
Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy
Su, X., Zhang, X., Liu, W., Yang, X., An, N., Yang, F., Sun, J., Xing, Y., & Shang, H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.003 · Cited by 47
Successful Targeting of the Warburg Effect in Prostate Cancer by Glucose-Conjugated 1,4-Naphthoquinones
Dyshlovoy, S. A., Pelageev, D. N., Hauschild, J., Borisova, K. L., Kaune, M., Krisp, C., Venz, S., Sabutskii, Y. E., Khmelevskaya, E. A., Busenbender, T., et al. (2019) · Cancers · doi:10.3390/cancers11111690 · Cited by 49
“Inhibition of topoisomerase-II [13,14] as well as formation of semiquinones and superoxide radicals resulting in dsDNA breaks [15] have been reported for some of these compounds (reviewed in [11,12]).”
Background
Relationship between esophageal atresia with tracheoesophageal fistula and vertebral anomalies in mammalian embryos
Merei, J. M., Hasthorpe, S., Farmer, P. J., & Hutson, J. M. (1998) · Journal of Pediatric Surgery · doi:10.1016/s0022-3468(98)90362-1 · Cited by 47
DNA unwinding and inhibition of T4 DNA ligase by anthracyclines
Montecucco, A., Pedrali‐Noy, G., Spadari, S., Zanolin, E., & Ciarrocchi, G. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.9.3907 · Cited by 47
Position-specific trapping of topoisomerase I–DNA cleavage complexes by intercalated benzo[ a ]- pyrene diol epoxide adducts at the 6-amino group of adenine
Pommier, Y. G., Laco, G. S., Kohlhagen, G., Sayer, J. M., Kroth, H., & Jerina, D. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190312697 · Cited by 47
Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes
Ferguson, L. R., & Baguley, B. C. (1996) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(96)00024-3 · Cited by 47
potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: Comparison to salmonella responses
Ashby, J., Tinwell, H., Glover, P. L., Poorman‐Allen, P., Krehl, R., Callander, R. D., & Clive, D. (1994) · Environmental and Molecular Mutagenesis · doi:10.1002/em.2850240107 · Cited by 47
Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein, R. J., & Smith, P. J. (1988) · PubMed · Cited by 47
Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Pommier, Y. G., Orr, A., Kohn, K. W., & Riou, J. (1992) · PubMed · Cited by 47
Inhibitors of DNA gyrase
Drlica, K., & Coughlin, S. A. (1989) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(89)90093-4 · Cited by 47
Topoisomerase I and II cleavage of adenovirus DNA in vivo: both topoisomerase activities appear to be required for adenovirus DNA replication
Schaack, J. B., Schedl, P. D., & Shenk, T. E. (1990) · Journal of Virology · doi:10.1128/jvi.64.1.78-85.1990 · Cited by 47
Inhibitory Properties of Antitumor Prostaglandins against Topoisomerases
Suzuki, K., & Uyeda, M. (2002) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.66.1706 · Cited by 46
Topoisomerases as Novel Targets for Cancer Chemotherapy
Bodley, A. L., & Liu, L. F. (1988) · Nature Biotechnology · doi:10.1038/nbt1188-1315 · Cited by 46
Self-citation
Mechanism and base specificity of DNA breakage in intact cells by neocarzinostatin
Kappen, L. S., Ellenberger, T. E., & GOLDBERG, I. H. (1987) · Biochemistry · doi:10.1021/bi00376a008 · Cited by 46
Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line
Patel, S., & Fisher, L. M. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.87 · Cited by 45
Inhibitors of topoisomerase II: Structure-activity relationships and mechanism of action of podophyllin congeners
Long, B. H., & Stringfellow, D. A. (1988) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(88)90019-2 · Cited by 45
Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.
Eder, J. P., Teicher, B. A., Holden, S. A., Cathcart, K. N. S., & Schnipper, L. E. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112983 · Cited by 45
Peptidyl Anthraquinones as Potential Antineoplastic Drugs: Synthesis, DNA Binding, Redox Cycling, and Biological Activity
Gatto, B., Zagotto, G., Sissi, C., Cera, C., Uriarte, E., Palù, G., Capranico, G., & Palumbo, M. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950924a · Cited by 45
Predominant role for DNA damage in etoposide-induced cytotoxicity and cell cycle perturbation in human SV40-transformed fibroblasts.
Smith, P. J., Anderson, C. O., & Watson, J. V. (1986) · PubMed · Cited by 45
Synthesis and Characterization of 4,11-Diaminoanthra[2,3-b]furan-5,10-diones: Tumor Cell Apoptosis through tNOX-Modulated NAD+/NADH Ratio and SIRT1
Tikhomirov, A. S., Shchekotikhin, A. E., Lee, Y., Chen, Y., Yeh, C.-A., Tatarskiy, V. V., Dezhenkova, L. G., Glazunova, V. A., Balzarini, J. M., Shtil, A. A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00859 · Cited by 44
Cytogenetical characterization of Chinese hamster ovary X-ray-sensitive mutant cells, xrs 5 and xrs 6 IV. Study of chromosomal aberrations and sister-chromatid exchanges by restriction endonucleases and inhibitors of DNA topoisomerase II
Darroudi, F., & Natarajan, A. T. (1989) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(89)90064-x · Cited by 44
The non-genotoxic hepatocarcinogen nafenopin suppresses rodent hepatocyte apoptosis induced by TGFbeta1, DNA damage and Fas
Gill, J. H. (1998) · Carcinogenesis · doi:10.1093/carcin/19.2.299 · Cited by 44
DNA signals for G2 checkpoint response in diploid human fibroblasts
Kaufmann, W. K., & Kies, P. E. (1998) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(98)00041-4 · Cited by 44
Drug-induced death of the asexual blood stages of Plasmodium falciparum occurs without typical signs of apoptosis
Nyakeriga, A. M., Perlmann, H., Hagstedt, M., Berzins, K., Troye‐Blomberg, M., Zhivotovsky, B., Perlmann, P., & Grandien, A. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2006.01.016 · Cited by 43
Thioguanine substitution alters DNA cleavage mediated by topoisomerase II
Krynetskaia, N. F., Cai, X., Nitiss, J. L., Krynetski, E. Y., & Relling, M. V. (2000) · The FASEB Journal · doi:10.1096/fj.00-0089com · Cited by 43
In vivo stimulation by antitumor drugs of the topoisomerase II induced cleavage sites in c-myc protooncogene
Riou, J., Multon, É. T., Vilarem, M., Larsen, C., & RIOU, G. F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)91189-7 · Cited by 43
The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor bearing mice
Gupta, S., Mathur, R., & Dwarakanath, B. S. R. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.1.1381 · Cited by 42
Epipodophyllotoxins in the treatment of childhood cancer
Rivera, G. K., Pui, C., Santana, V. M., Pratt, C. B., & Crist, W. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00684870 · Cited by 42
Mapping of a human centromere onto the DNA by topoisomerase II cleavage
Floridia, G., Zatterale, A., Zuffardi, O., & Tyler‐Smith, C. (2000) · EMBO Reports · doi:10.1093/embo-reports/kvd110 · Cited by 42
Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line
Lefevre, D., Riou, J., Ahomadegbe, J. C., Zhou, D., Bénard, J., & RIOU, G. F. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90138-u · Cited by 42
Reduced topoisomerase II and elevated α class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C
Hoban, P. R., Robson, C. N., Davies, S. M., Hall, A. G., Cattan, A. R., Hickson, I. D., & Harris, A. L. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90231-7 · Cited by 42
DNA topoisomerase II cleaves at specific sites in the 5′ flanking region of c‐fos proto‐oncogenes in vitro.
Darby, M. K., Herrera, R. E., Vosberg, H.-P., & Nordheim, A. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04493.x · Cited by 42
Design, Synthesis, and Cytotoxic Evaluation of a New Series of 3-Substituted Spiro[(dihydropyrazine-2,5-dione)-6,3‘-(2‘,3‘-dihydrothieno[2,3-b]naphtho-4‘,9‘-dione)] Derivatives
Gomez-Monterrey, I. M., Campiglia, P., Carotenuto, A., Califano, D., Pisano, C., Vesci, L., Lama, T., Bertamino, A., Sala, M., di Bosco, A. M., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0612158 · Cited by 42
A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization
Xu, G. W., Mawji, I. A., Macrae, C. J., Koch, C. A., Datti, A., Wrana, J. L., Dennis, J. W., & Schimmer, A. D. (2008) · APOPTOSIS · doi:10.1007/s10495-007-0175-4 · Cited by 41
“Thus, our findings suggest that a chemical biology approach can identify factors regulating p53 subcellular localization and function, and provide insights into the mechanism of action of ellipticine, a compound previously known to induce apoptosis in malignant cells [10, 11].”
Background
Natural Products as Pharmaceuticals and Sources for Lead Structures
Newman, D. J., Cragg, G. M. L., & Kingston, D. G. I. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374194-3.00008-1 · Cited by 41
Position-specific trapping of topoisomerase II by benzo[ a ]pyrene diol epoxide adducts: Implications for interactions with intercalating anticancer agents
Khan, Q. A., Kohlhagen, G., Marshall, R., Austin, C. A., Kalena, G. P., Kroth, H., Sayer, J. M., Jerina, D. M., & Pommier, Y. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2032456100 · Cited by 41
DNA Sequence Specificity for Topoisomerase II Poisoning by the Quinoxaline Anticancer Drugs XK469 and CQS
Gao, H., Yamasaki, E. F., Chan, K. K., Shen, L. L., & Snapka, R. M. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1382 · Cited by 41
“Different topoisomerase II poisons can cause very different patterns of strong and weak DNA cleavages (Tewey et al., 1984; Capranico et al., 1990; Pommier et al., 1992).”
Background
Etoposide protein binding in cancer patients
Liu, B., Earl, H. M., Poole, C. J., Dunn, J., & Kerr, R. S. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685801 · Cited by 41
Induction of sister chromatid exchanges by inhibitors of topoisomerases
Lim, M., Liu, L. F., Jacobson‐Kram, D., & Williams, J. R. (1986) · Cell Biology and Toxicology · doi:10.1007/bf00117850 · Cited by 41
Self-citation
Chromosomes with Two Intact Axial Cores Are Induced by G2 Checkpoint Override: Evidence That DNA Decatenation Is not Required to Template the Chromosome Structure
Andreassen, P. R., Lacroix, F., & Margolis, R. L. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.136.1.29 · Cited by 41
Pharmacogenomics as a Risk Mitigation Strategy for Chemotherapeutic Cardiotoxicity
Jensen, B. C., & McLeod, H. L. (2013) · Pharmacogenomics · doi:10.2217/pgs.12.205 · Cited by 40
DNA sequence specificity of mitoxantrone
Panousis, C., & Phillips, D. R. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.8.1342 · Cited by 40
Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations
Nakada, S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25716e1 · Cited by 40
Catalytic inhibition of human DNA topoisomerase IIα by hypericin, a naphthodianthrone from St. John’s wort (Hypericum perforatum)44Abbreviations: SJW, St. John’s wort; topo II, topoisomerase IIα; CAT, chloramphenicol acetyltransferase; and XRE, xenobiotic response element.
Peebles, K. A., Baker, R. K., Kurz, E. U., Schneider, B. J., & Kroll, D. J. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00759-6 · Cited by 40
Cisplatin and etoposide in oesophageal cancer: a phase II study
for the Rotterdam Oesophageal Tumour Study Group, Kok, T., van der Gaast, A., Dees, J., van Woerkom-Eykenboom, W. M. H., van Overhagen, H., Stoter, G., Tilanus, H., & Splinter, T. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.469 · Cited by 40
The role of topoisomerase II in drug resistance
Isabella, P. D., Capranico, G., & Zunino, F. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90333-7 · Cited by 40
Topoisomerase II expression and VM-26 induction of DNA breaks during spermatogenesis in Xenopus laevis
Morse‐Gaudio, M., & Risley, M. S. (1994) · Journal of Cell Science · doi:10.1242/jcs.107.10.2887 · Cited by 40
Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide Consequences for DNA inactivation
Mans, D. R. A., Lafleur, M. V. M., Westmijze, E. J., Horn, I. R., Bets, D., Schuurhuis, G. J., Lankelma, J., & Retèl, J. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90708-q · Cited by 40
Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives
Vann, K. R., Ergün, Y., Zencir, S., Öncüoğlu, S., Osheroff, N., & Topçu, Z. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.034 · Cited by 39
Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in adult male albino rats
Sheta, A., Elsakkar, M. S. A. H., Hamza, M., & Solaiman, A. A. (2016) · Human & Experimental Toxicology · doi:10.1177/0960327115627685 · Cited by 41
Cellular Resistance to Topoisomerase Poisons
Rubin, E. H., Li, T., Duann, P., & Liu, L. F. (1996) · Cancer treatment and research · doi:10.1007/978-1-4613-1267-3_10 · Cited by 39
Self-citation
Isoaurostatin, a Novel Topoisomerase Inhibitor Produced by Thermomonospora alba
Suzuki, K., Yahara, S., Maehata, K., & Uyeda, M. (2001) · Journal of Natural Products · doi:10.1021/np0004606 · Cited by 39
Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells
Fattman, C. L., Allan, W. P., Hasinoff, B. B., & Yalowich, J. C. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00338-3 · Cited by 39
Characterization of DNA topoisomerase I from Candida albicans as a target for drug discovery
Fostel, J. M., Montgomery, D., & Shen, L. L. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.10.2131 · Cited by 39
Effect of 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants.
Chang, J., Han, F. S., Liu, S.-Y., Wang, Z. Q., Lee, K., & Cheng, Y.-S. (1991) · PubMed · Cited by 39
Effect of ICRF-193, a Novel DNA Topoisomerase II Inhibitor, on Simian Virus 40 DNA and Chromosome Replication In Vitro
Ishimi, Y., Ishida, R., & Andoh, T. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.9.4007 · Cited by 39
Topoisomerases: Novel therapeutic targets in cancer chemotherapy
Hsiang, Y. H., Wu, H.-Y., & Liu, L. F. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90453-4 · Cited by 39
Self-citation
Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
Spiridonidis, C., Chatterjee, S., Petzold, S. J., & Berger, N. A. (1989) · PubMed · Cited by 39
Synthesis and evaluation of antitumor activity of 2- and 6-[(1,3-benzothiazol-2-yl)aminomethyl]-5,8-dimethoxy-1,4-naphthoquinone derivatives
Chung, Y., Shin, Y., Zhan, C., Lee, S., & Cho, H. (2004) · Archives of Pharmacal Research · doi:10.1007/bf02975839 · Cited by 38
Molecular Modeling of Wild-Type and D816V c-Kit Inhibition Based on ATP-Competitive Binding of Ellipticine Derivatives to Tyrosine Kinases
Vendôme, J., Letard, S., Martin, F., Svinarchuk, F., Dubreuil, P. C., Auclair, C., & Bret, M. L. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050231m · Cited by 38
Ellipticine increase the superhelical density of intracellular SV40 DNA by intercalation
chu, Y., & Hsu, M. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.15.4033 · Cited by 38
Teniposide, a topoisomerase II inhibitor, prevents chromosome condensation and separation but not decondensation in fertilized surf clam (Spisula solidissima) oocytes
Wright, S. J., & Schatten, G. P. (1990) · Developmental Biology · doi:10.1016/0012-1606(90)90166-g · Cited by 38
Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions
Zwelling, L. A., Mayes, J., Hinds, M., Chan, D., Altschuler, E. M., Carroll, B., Parker, E., Deisseroth, K. A., & Radcliffe, A. (1991) · Biochemistry · doi:10.1021/bi00230a032 · Cited by 38
Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents
Chen, T., Wu, C.-L., Lee, C.-C., Chen, C., Yü, D., & Huang, H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.050 · Cited by 37
The secondary Fusarium metabolite aurofusarin induces oxidative stress, cytotoxicity and genotoxicity in human colon cells
Jarolim, K., Wolters, K., Woelflingseder, L., Pahlke, G., Beisl, J., Puntscher, H., Braun, D., Sulyok, M., Warth, B., & Marko, D. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2017.12.008 · Cited by 38
Persistent DNA damage associated with ATM kinase deficiency promotes microglial dysfunction
Bourseguin, J., Cheng, W., Talbot, E., Hardy, L., Lai, J. F., Jeffries, A. M., Lodato, M. A., Lee, E. A., & Khoronenkova, S. V. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac104 · Cited by 36
Influence of DNA damage and repair upon the risk of treatment related leukemia
Guillem, V. M., & Tormo, M. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701769657 · Cited by 37
“They can be produced by replication errors, by endogenous agents – such as free radicals from oxidative metabolisms – and V(D)J recombination (which generates DSBs during rearrangement of B cell immunoglobulin and T cell receptor genes) [18], or by exogenous agents such as ionizing radiation [19] and anticancer drugs,…”
BackgroundInfluential
p21 response to DNA damage induced by genistein and etoposide in human lung cancer cells
Ding, H., Duan, W., Zhu, W., Ju, R., Srinivasan, K., Otterson, G. A., & Villalona-Calero, M. A. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00873-8 · Cited by 37
Vosaroxin: a novel antineoplastic quinolone
Abbas, J. A., & Stuart, R. K. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.699038 · Cited by 37
Molecular and Cellular Pharmacology of the Novel Noncamptothecin Topoisomerase I Inhibitor Genz-644282
Sooryakumar, D., Dexheimer, T. S., Teicher, B. A., & Pommier, Y. G. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1043 · Cited by 38
Neutral Porphyrin Derivative Exerts Anticancer Activity by Targeting Cellular Topoisomerase I (Top1) and Promotes Apoptotic Cell Death without Stabilizing Top1-DNA Cleavage Complexes
Das, S., Ghosh, A., Chowdhuri, S. P., Halder, N., Rehman, I., Sengupta, S., Sahoo, K. C., Rath, H., & Das, B. B. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01297 · Cited by 37
Repair of UV-induced lesions in Xenopus laevis oocytes.
Legerski, R. J., Penkala, J. E., Peterson, C. A., & Wright, D. A. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.12.4317 · Cited by 37
Rapid evaluation of topoisomerase inhibitors: Caffeine inhibition of topoisomerases in vivo
Shin, C., Strayer, J. M., Wani, M. A., & Snapka, R. M. (1990) · Teratogenesis Carcinogenesis and Mutagenesis · doi:10.1002/tcm.1770100106 · Cited by 37
Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines
Kanzawa, F., Nishio, K., Ishida, T., Fukuda, M., Kurokawa, H., Fukumoto, H., Nomoto, Y., Fukuoka, K., Bojanowski, K., & Saijo, N. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.428 · Cited by 37
“Clinically used DNA topoisomerase II inhibitors such as doxorubicin and etoposide act by stabilizing the cleavable complex (Nelson et al, 1984; Ross et al, 1984; Tewey et al, 1984).”
Background
Inhibition of Topoisomerases by Fatty Acids
Suzuki, K., Shono, F., Kai, H., Uno, T., & Uyeda, M. (2000) · Journal of enzyme inhibition · doi:10.1080/14756360009040693 · Cited by 37
Novobiocin inhibits RNA polymerase III transcriptionin vitroby a mechanism distinct from DNA topoisomerase II
Gottesfeld, J. M. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.5.2075 · Cited by 37
Interaction of topoisomerase 1 with the transcribed region of theDrosophilaHSP 70 heat shock gene
Kroeger, P. E., & Rowe, T. C. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.21.8495 · Cited by 37
2 Structural Aspects of Antineoplastic Agents – A New Approach
Cheng, C. (1988) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70277-7 · Cited by 37
DNA topoisomerases as targets for chemotherapy
Rose, K. M. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.9.2836254 · Cited by 37
Negative supercoiling is not required for 5S RNA transcription in vitro
Wolffe, A. P., Andrews, M. T., Crawford, E., Losa, R., & Brown, D. D. (1987) · Cell · doi:10.1016/0092-8674(87)90279-0 · Cited by 37
Bisindenoisoquinoline Bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA Intercalator and Topoisomerase Inhibitor with Antitumor Activity
Antony, S., Agama, K., Miao, Z., Hollingshead, M. G., Holbeck, S. L., Wright, M. H., Varticovski, L., Nagarajan, M., Morrell, A. E., Cushman, M., et al. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.024372 · Cited by 36
“Because DNA intercalators are known to trap Top2 (Tewey et al., 1984), we tested whether NSC 727357 also targets Top2.”
Background
Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells
Willmore, E., Errington‐Mais, F., Tilby, M. J., & Austin, C. A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00920-6 · Cited by 36
Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase II.
Markovits, J., Pommier, Y. G., Mattern, M. R., Esnault, C., Roques, B. P., Pecq, J. B. L., & Kohn, K. W. (1986) · PubMed · Cited by 36
Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin
Wahl, A. F., Donaldson, K. L., Mixan, B. J., Trail, P. A., & Siegall, C. B. (2001) · International Journal of Cancer · doi:10.1002/ijc.1364 · Cited by 36
Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog With Topoisomerase Inhibitory Properties
Tolcher, A. W., Eckhardt, S. G., Kuhn, J. G., Hammond, L. A., Weiss, G. R., Rizzo, J. D., Aylesworth, C. A., Hidalgo, M. M., Patnaik, A., Schwartz, G. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2937 · Cited by 36
Anthracycline resistance in murine leukemic P388 CELLS
Nair, S., Singh, S. V., Samy, T. S. A., & Krishan, A. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90151-a · Cited by 36
Quantitation of type II topoisomerase in oocytes and eggs of Xenopus laevis
Luke, M. M., & Bogenhagen, D. F. (1989) · Developmental Biology · doi:10.1016/0012-1606(89)90271-6 · Cited by 36
Non-SMC Element 2 (NSMCE2) of the SMC5/6 Complex Helps to Resolve Topological Stress
Verver, D. E., Zheng, Y., Speijer, D., Hoebe, R. A., Dekker, H. L., Repping, S., Stap, J., & Hamer, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111782 · Cited by 35

Authors: Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F.
Affiliations: Johns Hopkins University (US)
ORCID: Liu, L F
Venue: Journal of Biological Chemistry
Publisher: Elsevier BV
Published: 1984-07
Volume: 259
Issue: 14
Pages: 9182-9187
ISSN: 0021-9258 (ISSN-L)
DOI: 10.1016/s0021-9258(17)47282-6
OpenAlex: W1514525963
Cited by: 887
References: 39
Citations by year: 2026: 2 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 10 · 2019: 16 · 2018: 9 · 2017: 15 · 2016: 19 · 2015: 14 · 2014: 14 · 2013: 16 · 2012: 14
FWCI: 15.02
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor, 13270 d)
Locations: Journal of Biological Chemistry (publishedVersion, cc-by)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords: topoisomerase II, epipodophyllotoxins, etoposide, doxorubicin, cleavable complex, drug-enzyme interaction, nalidixic acid, DNA gyrase, cytotoxicity mechanism
MeSH terms: Alkaloids, Animals, Antineoplastic Agents, Cattle, DNA, DNA Topoisomerases, Type II, DNA Topoisomerases, Type I, DNA, Viral, Ellipticines, HeLa Cells, Humans, Intercalating Agents, Kinetics, Osmolar Concentration, Plasmids, Protein Binding, Thymus Gland

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks